Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Completed · Phase 2

Conditions studied: Choroidal Neovascularization, Age-Related Maculopathy

In brief

The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.

Key facts

Study ID

NCT00775411

Run by

Allergan

People needed

44

Starts

2008-11-01

Expected to finish

2010-04-01

Last updated by the study team

2012-09-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 50 years of age or older with active subfoveal choroidal neovascularization (CNV) secondary to AMD
• Central retinal thickness ≥ 300 µm
• Visual acuity between 20/400 and 20/32
• Eligible for Anti-VEGF therapy

You may not qualify if…

• Previous treatment for CNV due to AMD
• High eye pressure
• Glaucoma
• Uncontrolled systemic disease
• Known allergy to the study medications
• Recent eye surgery or injections in the eye
• Female subjects that are of childbearing potential

Where it is running

• Study site — San Antonio, Texas, United States
• Study site — Sydney, New South Wales, Australia
• Study site — Manila, Philippines

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.